R6569-ONC-1933 (Regeneron)
Description: A Phase 1 Study of REGN6569, an Anti-GITR mAb, with Cemiplimab in Patients with Advanced Solid Tumor Malignancies.
Mechanism of Action: Fully Human Monoclonal Antibody Targeting GITR plus cemiplimab (PD1 inhibitor)
Target Patient Population: All Solid Tumors, patients are put on a wait list
Study Design: Drug is administered IV every 3 weeks.